Date: 2018-08-07
Type of
information: Initiation of the trial
phase: 3
Announcement:
Company: Celltrion Healthcare (South Korea)
Product: CT-P17 (biosimilar version of Humira® - adalimumab)
Action
mechanism:
- monoclonal antibody/biosimilar product/TNF alpha inhibitor. CT-P17 is a biosimilar version of the monoclonal antibody adalimumab (Humira®). Adalimumab specifically binds to tumor necrosis factor (TNF)-alpha.
- Celltrion has developed CT-P17 as a high-concentration formulation and thus differentiated it from the competitive biosimilars which are conducting clinical trials or have already been approved.
Disease: rheumatoid arthritis
Therapeutic
area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Country:
Trial
details:
Latest
news:
- • ‘On August 7, 2018, Celltrion announced that the company conduct sglobal phase 3 clinical trials in about 75 sites in eight nations in European region from August 2018. It aims to complete phase 3 clinical trials by 2020.
Is
general: Yes
